Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • FDA approves new device for opioid withdrawal symptoms

    by
    • Optum Workers' Comp
    | Dec 13, 2017
    Tag Icon
    Opioids, FDA
    An electrical stimulation device has been granted an indication from the U.S. Food and Administration (FDA) for reducing opioid withdrawal symptoms. The FDA’s rapid expansion of the new indication for this device demonstrates its commitment to support novel ways to assist those who have been afflicted by opioid addiction.


  • New generic options available for Viagra®

    by
    | Dec 12, 2017
    Tag Icon
    FDA, Generics
    Teva Pharmaceuticals has launched a generic version of Viagra® (sildenafil) tablets, originally manufactured by Pfizer Inc. The patent for Viagra does not officially expire until 2020; however, Teva has been granted approval to launch its generic version now following a settlement with Pfizer in 2013.


  • Arkansas drug formulary receives legislative approval

    by
    | Dec 08, 2017
    Tag Icon
    Opioids, MED, formulary
    The Arkansas Workers’ Compensation Commission’s (ARWCC) most recent version of their Drug Formulary rule received approval by a legislative oversight committee. This approval permits the ARWCC to move forward with finalization and implementation of the drug formulary.


  • FDA has provided an update regarding Limbrel®

    by
    • Optum Workers' Comp
    | Dec 07, 2017
    Tag Icon
    FDA
    UPDATE: The U.S. Food and Drug Administration (FDA) has released a statement recommending that Primus Pharmaceuticals, Inc. voluntarily recall its medical food, Limbrel. The FDA is reminding patients to not take Limbrel due to the potential risk of drug-induced liver injury as well as a serious lung condition. Patients are also being advised to contact their health care provider immediately.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.